Peapod Lane Capital LLC Invests $1.03 Million in Nektar Therapeutics (NASDAQ:NKTR)

Peapod Lane Capital LLC bought a new stake in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,107,516 shares of the biopharmaceutical company's stock, valued at approximately $1,030,000. Peapod Lane Capital LLC owned about 0.60% of Nektar Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently modified their holdings of NKTR. Valence8 US LP purchased a new position in shares of Nektar Therapeutics in the third quarter valued at about $34,000. Intech Investment Management LLC purchased a new position in Nektar Therapeutics during the third quarter valued at $41,000. XTX Topco Ltd bought a new position in Nektar Therapeutics in the 3rd quarter worth about $46,000. Erste Asset Management GmbH bought a new position in shares of Nektar Therapeutics in the third quarter worth approximately $61,000. Finally, Moloney Securities Asset Management LLC lifted its position in Nektar Therapeutics by 42.4% in the 4th quarter. Moloney Securities Asset Management LLC now owns 50,000 shares of the biopharmaceutical company's stock valued at $46,000 after acquiring an additional 14,895 shares in the last quarter. Hedge funds and other institutional investors own 75.88% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. B. Riley started coverage on shares of Nektar Therapeutics in a research note on Wednesday, January 8th. They set a "buy" rating and a $4.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $6.50 price target on shares of Nektar Therapeutics in a report on Monday, January 13th. Finally, Piper Sandler began coverage on shares of Nektar Therapeutics in a research report on Monday, November 4th. They issued an "overweight" rating and a $7.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Nektar Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $4.08.

Insider Transactions at Nektar Therapeutics

In related news, CEO Howard W. Robin sold 46,995 shares of the firm's stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $1.01, for a total value of $47,464.95. Following the completion of the transaction, the chief executive officer now directly owns 1,195,710 shares of the company's stock, valued at approximately $1,207,667.10. This trade represents a 3.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jonathan Zalevsky sold 51,115 shares of the company's stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $0.94, for a total transaction of $48,048.10. Following the sale, the insider now owns 326,904 shares in the company, valued at $307,289.76. This represents a 13.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 155,575 shares of company stock valued at $149,878. 3.71% of the stock is currently owned by corporate insiders.

Nektar Therapeutics Stock Up 10.2 %

NKTR stock traded up $0.09 during midday trading on Monday, hitting $0.98. The company's stock had a trading volume of 6,871,913 shares, compared to its average volume of 1,319,271. Nektar Therapeutics has a 12 month low of $0.63 and a 12 month high of $1.93. The company has a 50 day moving average of $0.92 and a two-hundred day moving average of $1.12. The firm has a market capitalization of $181.25 million, a price-to-earnings ratio of -1.17 and a beta of 0.58.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.